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S UMMA R Y
OB J E C T I V E S : To understand the impact of past expe-
riences of anti-tuberculosis treatment among patients
co-infected with the human immunodeficiency virus and
multidrug-resistant tuberculosis (MDR-TB) on percep-
tions and attitudes towards treatment.
METHODS : Qualitative study using in-depth interviews
with 12 HIV-MDR-TB co-infected patients in Mumbai,
India.
R E SU LT S : Patients reported unnecessarily long path-
ways to care and fatigue with diagnostic and treatment
procedures. In particular, they expressed concerns over
the lack of efficacy of their current treatment regimen
based on their experiences with anti-tuberculosis treat-
ment regimens in the past.
CONC LU S I ON : Patients reported negative experiences
with previous HIV and anti-tuberculosis treatment.
Access to early diagnosis and rapid initiation of
integrated care for HIV-MDR-TB co-infected patients,
with a strong, patient-centered support system, could
help to combat the low morale and lack of faith in
treatment described in this group of patients.
K E Y WO RD S : human immunodeficiency virus; TB-
HIV; multidrug-resistant tuberculosis; treatment adher-
ence; qualitative study; India; operational research
TUBERCULOSIS (TB) is one of the main infectious
diseases in the world today, with more than eight
million cases and one million deaths reported
annually.1 Multidrug-resistant forms of TB (MDR-
TB, defined as strains ofMycobacterium tuberculosis
with in vitro resistance to at least isoniazid and
rifampin)2 are becoming an increasing global public
health problem.3 These strains have been associated
with higher degrees of morbidity and mortality than
pan-susceptible strains,4,5 although acceptable out-
comes can be achieved under certain conditions.6
Such conditions require early diagnosis, timely access
to appropriate treatment and regular treatment for a
period of 18–24 months.7
Although access to diagnosis and treatment for
MDR-TB is improving worldwide, significant gaps
still need to be addressed.8 The majority of patients
do not have access to drug susceptibility testing (DST)
at the time of TB diagnosis, and are thus started on
empiric TB treatment.9,10 While this treatment is
successful in the majority of cases, substantial
populations of individuals infected with drug-resis-
tant strains of TB do not benefit from this empiric
treatment.11 In addition to suffering increased mor-
bidity and mortality, as well as the possibility of
recruiting additional resistance to TB during empiric
treatment,12 these individuals remain infectious.13
For these reasons, multiple public health and advo-
cacy groups have called for more timely diagnosis of
and treatment for MDR-TB.14,15
The potential public health consequences of late
diagnosis and treatment for MDR-TB have been
described.16–18 However, the impact of previous anti-
tuberculosis treatment on patients’ current experi-
ences of MDR-TB treatment, especially among HIV
co-infected patients, has not been reported. An
understanding of the experiences of these patients is
important, as such experiences may affect patient
outcomes, particularly adherence to treatment.
The objective of this qualitative study is to explore
the experiences of a group of co-infected MDR-TB-
HIV patients who had received anti-tuberculosis
treatment in the past, with a focus on understanding
how such past experiences impact their current
perceptions of treatment.
METHODS
Setting
The study took place at an out-patient MDR-TB
treatment program supported by Me´decins Sans
Frontie`res (MSF) in the city of Mumbai, India. MSF
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began treating MDR-TB among HIV-infected pa-
tients in May 2007, and by April 2012 the cohort had
registered a total of 120 patients. Patients received
treatment through an ambulatory community-based
program described elsewhere.19 The data presented in
this paper are drawn from a larger qualitative study
conducted between April and October 2012 among
patients with HIV and MDR-TB and their care
givers.20
Participants
Thirty-three patients were actively receiving treat-
ment at the time the study was conducted. Twelve of
these patients were purposively selected to participate
in the larger qualitative study described above, and
data from these individuals are included in this
subanalysis. Patient interviews were conducted in
Hindi or Marathi and covered their experiences of
help seeking prior to enrolment at the MSF clinic.
Data collection
Data were collected between May and September
2012. Informed consent was obtained from all
participants before the interview. In-depth interviews
were conducted with participating patients by an
experienced qualitative researcher who was external
to the program and spoke the three languages
common to the patients interviewed (Hindi, Marathi,
English). The majority of the interviews were
recorded using a digital recorder, transcribed and
translated into English. Notes were taken in cases
where the respondents did not wish to be recorded
and were expanded immediately afterwards.
Data analysis
A thematic analysis was performed to analyze the
data in the study.21 The data transcripts were read
and reviewed manually by one of the medical
anthropologists on the team (JF). First, the larger
data set was read through to assess patient reports of
previous treatment experiences. A number of themes
were uncovered during this initial review, all of which
were transcribed onto note cards with corresponding
patient ID numbers and thematic codes. The second
and third reviews were performed to further refine the
themes, identify and code any subthemes, and group
responses according to subtheme. A fourth review
enabled verification of the subthemes that had
emerged in previous reviews of the data. Finally, a
second investigator (PI) reviewed the transcripts to
enable cross-validation of the themes identified.
Differences in interpretation were discussed and
resolved by the two investigators.
Ethics
The study was approved by the Institutional Review
Board of the Maharashtra Association of Anthropo-
logical Sciences – Centre for Health Research and
Development, Pune, India. The MSF Ethics Review
Board, Geneva, Switzerland, reviewed the protocol
and advised on the study. Patients were given
information about the purpose of the study and their
role within it, and informed consent was obtained
from them if they were available and willing to
participate.
RESULTS
Patient characteristics
Of the 12 respondents, 8 were men, 3 were women
and 1 was transgender (TG). All except one were
between 35 and 55 years; the TG was 25 years old.
Most of the respondents had completed only a few
years of schooling; only one female respondent had 2
years of college education. Almost all the respondents
were residents of Mumbai and its extended suburbs.
One male respondent had completed treatment and
one man and one woman were about to complete
treatment at the time of interview. Of the remaining
9, 6 were in the intensive phase of treatment and 3
were in the continuation phase. The patients reported
a median of 2.2 previous courses of anti-tuberculosis
treatment, a median of 33 months of combined length
of previous treatments and a median of 4.5 treatment
institutions where the previous anti-tuberculosis
treatment had been provided.
Thematic areas
Three main themes pertaining to previous experience
of anti-tuberculosis treatment emerged from the data:
1) long pathways to care before the initiation of
MDR-TB treatment, 2) diagnostic and treatment
fatigue, and 3) lack of faith in treatment efficacy.
Long pathways before MDR-TB treatment initiation
All 12 patients described long and complicated
pathways of care before being diagnosed and started
on treatment for MDR-TB. Patients were sent from
one public or private facility to another, made
multiple visits to see the doctor and waited for long
periods before they received treatment for MDR-TB.
Similar experiences were also reported when receiv-
ing HIV treatment. This resulted in all of the patients
going through one and often two courses of first-line
anti-tuberculosis treatment before they were investi-
gated for MDR-TB and reached MSF for their
treatment. The experience of patient P06, a 41-year-
old male who was sick for two and half years before
receiving appropriate MDR-TB treatment, is typical
of what was described by patients in the study:
I had an ear infection and there was pus coming out of
my ear. I had to go to K (municipal hospital) to get
operated for that (. . .). That’s when it was found that I
have HIV (. . .). Then I had this back problem and I
could not move my leg properly. The doctor said that
this could be because of water in the spine (. . .) I was
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sent to the bone doctor. He was avoiding to do an
operation and my condition worsened. For a year and
a half, the doctors could not even tell me if I had TB.
They could see the TB in the X-ray but not in the
sputum. They would ask me to test the saliva all the
time and I got fed up with that as there was nothing
showing in that. They just kept testing the sputum
and that was negative. It is only when they took the
spinal fluid out that they found I had TB. So for 6
months I took [TB] pills from K. Then when they did
an X-ray again the patch had increased. They said I
have to start something called ‘tack two’ [referring to
Cat 2 regimen]. So I started that and took it for 4
months but that made me worse. I could not sit or
stand at all. They then removed the water from my
back and they checked it at H (private hospital) and
they found that I have MDR-TB and they asked me if
I can take medicines from outside. I told them that I
could not afford that so they sent me here to MSF. I
could not even walk at the time (P06).
Moreover, patients diagnosed in the private sector
typically incurred significant expenses. Just over half
of the patients described waiting for long periods of
time before they were able to find the money or
before finding a charity that could support their
treatment. As few providers knew about the free MSF
treatment for MDR-TB and second-/third-line anti-
retroviral therapy (ART), patients took time to reach
MSF even after being diagnosed with MDR-TB.
Several, like Patient P12, a 36-year-old woman who
was sick for 3 years and saw at least six different
practitioners before receiving her MDR-TB and HIV
treatment, expressed feeling physically, financially
and emotionally drained by the time they reached
MSF:
The doctor [at the public sector hospital] did not say
it directly . . . he said it would be little expensive. I
thought it will be a 1000 [rupees] or so but when I
went to buy it I found out that it will be 12 000 or
14 000 per month and I would have to take it for at
least 2 years. I did not have the capacity to spend that
much. And I have lost courage and hope too. My sons
too were not working at that time. It took long [2
months] to find out where I could get the support for
cost of medications. (. . .) So first I looked around. At
that time, 4–5 years had passed and [I thought] that
another couple of months would not make much
difference. If the condition of a person is so bad, the
person is bedridden, what can this person do? (P12)
Diagnostic and treatment fatigue
The majority of the patients interviewed expressed
being tired or ‘fed up’ with having to undertake
several diagnostic tests and/or taking medications.
Most of them had to undergo a battery of diagnostic
tests by different providers before they would even be
considered for MDR-TB treatment, including X-rays,
blood tests and hearing tests. As some of these tests
were not available at the same diagnostic centers, the
majority of the patients reported having to make trips
to several facilities. All of them noted the difficulty of
undertaking multiple tests, especially when they were
feeling physically unwell. The exhaustion reported by
Patient P3, a 53-year-old man with HIV and MDR-
TB, was commonly shared:
There was confusion when the people at [Hospital A]
made me run here and there. They got me tested for
different things. They used to call me on different
days for different tests. Sometimes they used to ask
me to get the X-ray performed in 4 days and after 4
days get other tests done. Then they used to give me
15 days’ time and told me to get the report. It used to
take a lot of time. The area over there is very big. (P3)
Just over half of the patients interviewed (7/12) also
reported fatigue over having to take medicines for
long periods of time. Typically, these individuals had
received at least two previous courses of anti-
tuberculosis treatment, which consisted of two to
four medications taken daily for a minimum of 6
months per treatment. HIV treatment consisted of
three medications taken once or twice a day for life,
along with at least one other tablet taken daily to
prevent infection. Treatment for MDR-TB required
taking five to six medications daily for 18–24months,
and most of the daily doses of each medication
required two to three tablets each. At the time of the
study, the patients were at different stages of MDR-
TB treatment, which is often associated with severe
side effects and daily injections. The large pill burden,
the duration of their current treatments for HIV and
MDR-TB and the long pathways described above left
many of the patients tired, and at times angry. Patient
P13, a 38-year-old male whose wife had died of HIV,
described the frustration of most of the patients in the
study:
To speak about myself, I really think it is difficult to
express. Taking so many tablets, going through so
much pain, I am fed up. (P13)
Patient P09, a 25-year-old TG individual, echoed
other patients when she voiced a sense not only of
fatigue with treatment but with life in general:
I used to feel that I take so many pills and an injection
and do not eat well. I am not getting better. I would
feel, what is the use of life like this? So I used to sit in a
lot of tension. (P09)
Lack of faith in treatment efficacy
More than half of the patients interviewed (7/12)
expressed concern that their current treatment might
not work or they might not be cured of MDR-TB.
Most of the patients in the study had received at least
one course of treatment that did not cure them of TB
(likely due to the fact that they had drug resistance
from the start, but were empirically treated for pan-
susceptible TB), and many of them had received two
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previous courses of anti-tuberculosis treatment and
were still suffering from the disease. It was common
for such individuals to no longer believe that their TB
could be cured. When this experience of not being
cured was combined with the messages they received
about HIV not being a ‘curable disease’, many
patients expressed a general sense that even with
medications they would not get better. The despair of
such patients was articulated by patient P06, a 41-
year-old male who underwent three courses of anti-
tuberculosis treatment:
I had all kinds of thoughts. I thought that I would
never get better now. What the use of living like this
was? I was sure that there is no way to get better with
all this. I would think about suicide. I thought what
was the use of taking so many medicines if there is no
hope of a cure. (P06)
Lack of faith in treatment efficacy also stemmed
from the fact that many patients perceived that
previous treatments as well as the current regimen
made them feel more ill, rather than providing relief
or curing them. Again, patient P06 described this very
clearly:
It was not a good time as I took the pills and kept
going there all the time. There were no visible signs of
any benefit at the time. It was more problematic – it
worsened my condition. (P06)
While many patients were concerned about the
lack of efficacy of their treatment based on their
own experiences, some of them also reported that
they were told by care givers that treatment would
not work for them. According to many patients,
doctors, nurses, and treatment supporters had
doubts about the treatment the patients were
receiving and expressed this doubt either directly
in conversation with the patient or with other staff
in front of the patients. Patient P08 was a 35-year-
old man who was sick for almost 2 years before he
was started on MDR-TB and HIV treatment. His
lack of faith in treatment came from what he heard
from providers:
So here, doctors, sisters [nurses] would all say: ‘what
is happening? . . . the medicines are not affecting you
. . . the medicines should work in a month or two.
(P08)
For some patients, the loss of faith in their
medications was mitigated by family support and,
more generally, by having a strong social support
system. Thus, while they themselves reported having
little faith in the power of treatment to make them
well, they were encouraged by friends and family
around them. The positive experiences of such
individuals are reflected in the words of Patient
P02, a 40-year-old man living with his wife and
extended family:
I do not think what will happen to me? What will
happen tomorrow? I feel I will deal with whatever
comes my way. I never have tension. [English word
used]. I believe that whatever has happened has
happened and I have to live with it . . . The best part is
that I have a lot of support from my family, my wife,
and my parents (P02).
DISCUSSION
To our knowledge, this is the first qualitative study of
an Indian cohort of HIV-MDR-TB co-infected
patients providing insight on how patients’ experi-
ences with previous anti-tuberculosis treatment might
affect their current treatment experiences.
This study reveals some disturbing themes in a
population of patients undergoing treatment for
MDR-TB and HIV in Mumbai. All of the patients
interviewed in the study reported unnecessarily long
pathways to care, and the majority reported a high
level of fatigue related to both diagnosis and
treatment. This feeling may be associated with an
increased risk for loss to follow-up from treatment
and care, especially given the pill burden and duration
of current treatment for MDR-TB.22,23 Studies on
other diseases, including HIV, asthma and hyperten-
sion, show a clear association between delays in
accessing care and poor treatment outcomes as well
as a sense of exhaustion with treatment and poor
treatment outcomes.24–26 Of note, the pathways to
care among co-infected patients were usually longer
than those infected with HIV or MDR-TB alone, as
care for TB and HIV is not integrated in most
programmes in India.
The majority of the patients in this study also
expressed a loss of faith in the efficacy of their
current treatment regimen based on their previous
treatment experiences. This loss of faith may directly
affect adherence to a long and difficult treatment
regimen such as the one used for MDR-TB.27
Perceived lack of efficacy has been noted to be
linked with poor outcomes of a number of diseases,28
and studies conducted among persons with HIV have
found that a perceived lack of treatment efficacy was
one of the primary reasons why people discontinued
ART.29
There are a number of public health implications
from this study. First, the findings suggest the need
to reduce time to diagnosis and initiate appropriate
treatment for MDR-TB to restore patients’ and
family members’ faith in treatment efficacy and
reduce the risk of treatment fatigue. Second, our
findings suggest that in Mumbai, as in other settings
with a high burden of drug-resistant TB, patients
continue to be treated with empiric first-line anti-
tuberculosis treatment without performing system-
atic DST, mainly due to limited resources. This may
result in a population of patients being subjected to
4 The International Journal of Tuberculosis and Lung Disease
ineffective treatment,30,31 with attendant medical
consequences.31,32 Increased access to DST in these
settings is required to address these concerns.
Third, the study also reveals diagnostic/treatment
fatigue and loss of faith in treatment efficacy that
could affect adherence to treatment and adversely
affect MDR-TB treatment outcomes, as has been
reported in pan-susceptible TB.33 The introduction of
rapid molecular methods for diagnosis of MDR-TB
could accelerate the initial diagnosis of MDR-TB.34
Along with improved diagnostics is the need for
rapid initiation of appropriate MDR-TB treatment,
as recent studies have shown that a substantial
proportion of patients diagnosed with MDR-TB
never initiated treatment.35 Given the challenging
current treatment options we offer to patients, a
strong psychosocial component should be part of
every MDR-TB treatment program, and patients and
their families should be supported throughout their
efforts to be diagnosed, initiate treatment and
successfully complete treatment.
Some limitations to this study need to be acknowl-
edged. As the analysis draws on a larger qualitative
study that did not have treatment experience as the
main focus, some experiences may have been under-
reported. We were also not able to probe into some
topics, as would be the case in the primary study.
However, the themes that were revealed were quite
clear and consistent. The study was limited to a
specific context (i.e., a group of patients being treated
at anMSF clinic) and reported on co-infected patients
only; their experiences may therefore not be repre-
sentative of the wider, global cohort of MDR-TB
patients. However, we believe that the data reflect
diversity in experiences and views. A strength of this
methodology is that it can uncover aspects of patient
experiences that may not be revealed in more
structured and quantitative studies, and also allows
the description of the context in which these
experiences occur. Variations in context should,
however, be considered before generalizing these
results to other settings
In conclusion, this qualitative study revealed a
significant burden of suffering among HIV-MDR-TB
co-infected patients in Mumbai. Long delays in
diagnosis and treatment and previous experience of
substandard treatment had led to profound physical
and mental fatigue among the patients and a sense of
hopelessness regarding their recovery. There is a clear
need to examine the treatment-seeking pathways of
patients with MDR-TB and HIV and to identify the
critical points at which delays are incurred and
patients’ time, money and energy are expended at
severe cost to themselves and their families.
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R E S UM E
OB J E C T I F S : Comprendre l’impact de l’expe´rience d’un
traitement passe´ de la tuberculose (TB) chez des patients
co-infecte´s par le virus de l’immunode´ficience humaine
(VIH) et une TB multire´sistante (TB-MDR), sur leurs
perceptions et attitudes vis-a`-vis du traitement.
M E´ THODE S : Etude qualitative base´e sur des entretiens
approfondis avec 12 patients co-infecte´s par le VIH et
une TB-MDR a` Mumbai, Inde.
R E´ S U LTAT S : Les patients se sont plaints d’un
cheminement inutilement long vers le traitement et
d’une fatigue tre`s importante lie´e aux proce´dures de
diagnostic et de traitement. Ils se sont montre´s
particulie`rement pre´occupe´s par l’inefficacite´
potentielle de leur protocole de traitement actuel en
fonction de leur expe´rience des protocoles de traitement
du passe´.
C O N C L U S I O N : Les patients ont rapporte´ des
expe´riences ne´gatives de leurs pre´ce´dents traitements
du VIH et de la TB. L’acce`s a` un diagnostic pre´coce et
une mise en route rapide d’un traitement inte´gre´ du VIH
et de la TB-MDR des patients co-infecte´s, couple´e a` un
syste`me de soutien solide, centre´ sur le patient, pourrait
contribuer a` lutter contre la baisse de moral et le manque
de confiance dans le traitement e´voque´s par ce groupe de
patients.
R E S UM E N
O B J E T I V O S: Comprender la repercusio´n de las
experiencias anteriores con el tratamiento
antituberculoso en personas que padecen coinfeccio´n
por el virus de la inmunodeficiencia humana (VIH) y
tuberculosis multidrogorresistente (TB-MDR) y evaluar
las percepciones y actitudes de los pacientes frente al
tratamiento.
M E´ TODO S: Se llevo´ a cabo un estudio cualitativo
mediante entrevistas en profundidad a 12 pacientes
que presentaban coinfeccio´n por el VIH y TB-MDR en
Mumbai, en la India.
R E S U LTA DO S: Los pacientes refirieron mecanismos
innecesariamente prolongados hasta la obtencio´n de
atencio´n sanitaria y una gran fatiga con los
procedimientos diagno´sticos y terape´uticos. Expresaron
sobre todo preocupacio´n con la falta de eficacia de su
tratamiento actual, dadas sus experiencias con regı´menes
antituberculosos recibidos en el pasado.
CONC LU S I O´ N: Los pacientes notificaron experiencias
negativas con los tratamientos previos contra el VIH y la
TB. Lograr el acceso al diagno´stico precoz y comenzar
prontamente una atencio´n integrada de la infeccio´n por
el VIH y la TB-MDR en los pacientes coinfectados,
mediante un sistema de apoyo eficaz centrado en el
paciente, podrı´a contribuir a combatir la
desmoralizacio´n y la falta de confianza en el
tratamiento recetado a este grupo de personas.
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